|Bid||54.00 x 1300|
|Ask||0.00 x 1400|
|Day's range||68.01 - 71.08|
|52-week range||52.51 - 80.71|
|Beta (3Y Monthly)||1.56|
|PE ratio (TTM)||23.52|
|Earnings date||7 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||80.75|
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of DaVita Inc. breached their fiduciary duties to shareholders. DaVita Inc.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LOS ANGELES (AP) — A health care company has agreed to pay $270 million to resolve allegations it provided inaccurate information to Medicare, federal prosecutors said Monday.
Shares of dialysis clinic operator DaVita rose more than 3 percent on Monday after California's governor vetoed a bill that would have cut into its sales.
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
DaVita (DVA) reported revenues of ~$2.9 billion in the second quarter of 2018, which is a 6.9% YoY (year-over-year) growth compared to $2.7 billion in the second quarter of 2017. DaVita reported 6.9% growth in its top line to $2.89 billion, including an 11.1% growth in revenues from US dialysis and related lab services to $2.57 billion, offset by a 17.7% decrease in revenues for other ancillary services and strategic initiatives in the second quarter of 2018. Medicare and Medicare Advantage revenues were $1.5 billion in the second quarter of 2018, a 16.2% growth compared to $1.3 billion in the second quarter of 2017.
DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita (DVA) released its second-quarter earnings after the market closed on August 1. It surpassed Wall Street analysts’ estimates for revenues and EPS and reported non-GAAP EPS of $1.15 on revenues of $2.9 billion. The EPS estimate was $0.97 on revenues of $2.8 billion.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 8.25% and 0.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Denver-based company said it had profit of $1.53. Earnings, adjusted for one-time gains and costs, came to $1.05 per share. The results topped Wall Street expectations. The average ...
As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.”
DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.
Sep.24 -- Kent Thiry, DaVita Inc.'s chairman and chief executive officer, discusses how the company is navigating a changing health-care landscape with Bloomberg's Ed Hammond on "Bloomberg Markets." DaVita's lead director is Peter Grauer, chairman of Bloomberg LP, parent company of Bloomberg News.